Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $22.50 Average Price Target from Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS) has been assigned an average rating of “Buy” from the six analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $22.50.

A number of research analysts have commented on the company. SVB Leerink boosted their price objective on Gossamer Bio from $15.00 to $16.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 9th. Zacks Investment Research upgraded Gossamer Bio from a “sell” rating to a “hold” rating in a research note on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Gossamer Bio in a research note on Monday, October 18th. Finally, Piper Sandler assumed coverage on Gossamer Bio in a research note on Monday, September 20th. They set a “buy” rating and a $26.00 price objective on the stock.

Gossamer Bio stock traded down $0.29 during midday trading on Thursday, reaching $11.25. The stock had a trading volume of 330,112 shares, compared to its average volume of 562,857. Gossamer Bio has a twelve month low of $7.04 and a twelve month high of $14.30. The stock has a market capitalization of $860.22 million, a PE ratio of -3.45 and a beta of 0.95. The company has a debt-to-equity ratio of 1.04, a quick ratio of 10.42 and a current ratio of 10.42. The stock’s 50-day simple moving average is $12.43 and its 200 day simple moving average is $9.98.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Monday, November 8th. The company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.02). During the same quarter in the previous year, the business posted ($0.80) earnings per share. Equities analysts predict that Gossamer Bio will post -3.17 earnings per share for the current fiscal year.

In other news, insider Laura Carter sold 2,377 shares of Gossamer Bio stock in a transaction dated Monday, October 25th. The stock was sold at an average price of $12.25, for a total transaction of $29,118.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.00% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in GOSS. Advisor Group Holdings Inc. increased its holdings in Gossamer Bio by 193.1% in the second quarter. Advisor Group Holdings Inc. now owns 3,567 shares of the company’s stock valued at $29,000 after buying an additional 2,350 shares during the last quarter. Royal Bank of Canada increased its holdings in Gossamer Bio by 62.0% in the first quarter. Royal Bank of Canada now owns 3,840 shares of the company’s stock valued at $36,000 after buying an additional 1,470 shares during the last quarter. Metropolitan Life Insurance Co NY increased its holdings in Gossamer Bio by 57,666.7% in the second quarter. Metropolitan Life Insurance Co NY now owns 8,665 shares of the company’s stock valued at $70,000 after buying an additional 8,650 shares during the last quarter. Close Asset Management Ltd bought a new stake in Gossamer Bio in the third quarter valued at about $72,000. Finally, Texas Yale Capital Corp. bought a new position in shares of Gossamer Bio during the second quarter valued at approximately $81,000. 68.86% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.

Featured Article: How to Use the MarketBeat Retirement Calculator

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.